Approved treatments
for IgaN
Fabhalta
Fabhalta (iptacopan) is an oral therapy approved to preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. It is taken as oral capsules twice daily.
Filspari
Filspari is an oral therapy approved to slow the decline in kidney function in adults with primary immunoglobulin A nephropathy (IgAN). It is taken as oral tablets once daily.
Tarpeyo
Tarpeyo is an oral therapy approved to slow the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. It is taken daily in the form of oral capsules for nine months.
Trutakna
Trutakna is an injection therapy approved to treat adults with immunoglobulin A nephropathy (IgAN) who are at a high risk of disease progression. It is given via under-the-skin injections once weekly.
Ultomiris
Ultomiris (ravulizumab) is an approved treatment for adults with IgAN who are at risk of disease progression. Delivered via infusions into the bloodstream every eight weeks, the medication is designed to block an immune pathway that contributes to kidney damage in IgAN.
Vanrafia
Vanrafia is an oral therapy approved for adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. It is taken in the form of oral tablets once daily.
Voyxact
Voyxact is an injectable therapy approved to reduce excessive protein in the urine (proteinuria) for adults with immunoglobulin A nephropathy who are at risk of disease progression. It is given as a monthly injection under the skin.